Treatment of t-cell mediated diseases

Abstract

The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

1 - 91 . (canceled) 
     
     
         92 . A pharmaceutical composition comprising albumin and an aspartic acid-alanine diketopiperazine (DA-DKP) or a physiologically-acceptable salt thereof, wherein the composition is formulated for topical or transdermal administration. 
     
     
         93 . The composition of  claim 92 , wherein the composition is formulated for topical administration. 
     
     
         94 . The composition of  claim 93 , wherein the composition is an ointment, a paste, a cream, a lotion, or a gel. 
     
     
         95 . The composition of  claim 92 , wherein the composition is formulated for transdermal administration. 
     
     
         96 . The composition of  claim 95 , wherein in the composition is in a transdermal patch. 
     
     
         97 . The composition of  claim 92 , wherein the composition is formulated for slow or controlled release. 
     
     
         98 . The composition of  claim 92 , wherein the composition is administered to a subject having a T-cell mediated disease. 
     
     
         99 . A method to treat a subject having a T-cell mediated disease comprising administering a composition comprising albumin and DA-DKP or a physiologically-acceptable salt thereof topically to the subject. 
     
     
         100 . The method of  claim 99 , wherein the T-cell mediated disease is a T-cell mediated autoimmune disease. 
     
     
         101 . The method of  claim 100 , wherein the T-cell mediated autoimmune disease is selected from the group consisting of psoriasis, rheumatoid arthritis, neuritis and scleroderma. 
     
     
         102 . A method to treat a subject having a T-cell mediated disease comprising administering a composition comprising albumin and DA-DKP or a physiologically-acceptable salt thereof transdermally to the subject. 
     
     
         103 . The method of  claim 102 , wherein the T-cell mediated disease is a T-cell mediated autoimmune disease. 
     
     
         104 . The method of  claim 103 , wherein the T-cell mediated disease is selected from the group consisting of psoriasis, rheumatoid arthritis, neuritis and scleroderma.